Pharmaceutical composition and use thereof
Patent Information
- Application Number
- MYPI2025001543
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-09
- Filing Date
- 2023-06-01
- Publication Date
- 2024-03-09
AI Technical Summary
Existing cancer treatment methods have limited therapeutic effects on various tumor types, especially in non-small cell lung cancer, renal cell carcinoma, ovarian cancer, etc. Traditional methods are difficult to effectively control the disease, and have high toxicity and poor efficacy. .
The combination of anti-CTLA4-anti-PD-1 bispecific antibody and anti-PD-1-anti-VEGFA bispecific antibody synergistically enhances the immune response to inhibit tumor growth by targeting the CTLA4, PD-1 and VEGFA signaling pathways.
This combination of drugs is significantly better than a single drug combination, can effectively inhibit tumor growth, improve treatment effects, provide a lower toxicity and more efficient treatment plan, and is especially suitable for various types of cancer.
Smart Images

Figure PI2025001543_DRAWING_001 
Figure PI2025001543_DRAWING_002
Abstract
Description
Drug combinations and uses Technical Field
[0001] The present invention belongs to the fields of tumor therapy and molecular immunology, and specifically relates to drug combinations and uses. Specifically, the drug combination is a pharmaceutical composition or combination product. Specifically, the pharmaceutical composition or combination product comprises an anti-CTLA4-anti-PD-1 bispecific antibody or an antigen-binding fragment thereof, and an anti-PD-1-anti-VEGFA bispecific antibody or an antigen-binding fragment thereof. Background Art
[0002] The transmembrane receptor PD-1 (programmed cell death-1) is a member of the CD28 gene family and is expressed on activated T cells, B cells, and myeloid cells. PD-1's ligands, PDL1 (programmed cell death 1 ligand 1, also abbreviated as PD-L1) and PDL2 (programmed cell death 1 ligand 2, also abbreviated as PD-L2), both belong to the B7 superfamily. PDL1 is expressed on a variety of cells, including T cells, B cells, endothelial cells, and epithelial cells, while PDL2 is only expressed on antigen-presenting cells such as dendritic cells and macrophages.
[0003] The PD-1 / PDL1 signaling pathway plays a crucial role in regulating immune tolerance, microbial infection, and tumor immune evasion. PD-1 is primarily expressed in immune cells such as T cells, while its ligand, PDL1, is highly expressed in many human tumor tissues. Blocking the PD-1 / PDL1 signaling pathway can reactivate suppressed T cells, allowing them to attack cancer cells. Blocking PD-1 / PDL1 signaling promotes the proliferation of tumor antigen-specific T cells, which kill tumor cells and thereby inhibit local tumor growth (Julie R et al., 2012, N Engl J Med. 366:2455–2465). Furthermore, tumors with high PDL1 expression are associated with cancers that are difficult to detect (Hamanishi et al., 2007, Proc. Natl. Acad. Sci. USA 104:3360–5). One effective approach is to modulate PD-1 expression through in vivo administration of anti-PD-1 antibodies. Due to the broad-spectrum anti-tumor potential and amazing efficacy of PD-1 antibodies, the industry generally believes that antibodies targeting the PD-1 pathway will bring breakthrough progress in the treatment of various tumors: for the treatment of non-small cell lung cancer, renal cell carcinoma, ovarian cancer, melanoma (Homet MB, Parisi G., et al., 2015, Semin Oncol. 42(3): 466-473), leukemia and anemia (Held SA, Heine A, et al., 2013, Curr Cancer Drug Targets. 13(7): 768-74).
[0004] Cytotoxic T lymphocyte associated antigen 4 (CTLA4) and CD28 share a very similar relationship in terms of gene structure, chromosomal location, sequence homology, and gene expression. Both are receptors for the costimulatory molecule B7 and are primarily expressed on the surface of activated T cells. CTLA4, upon binding to B7, inhibits the activation of mouse and human T cells, playing a negative regulatory role in T cell activation.
[0005] CTLA4 antibodies (or anti-CTLA4 monoclonal antibodies) or CTLA4 ligands can prevent CTLA4 from binding to its natural ligand, thereby blocking CTLA4's ability to transmit negative regulatory signals to T cells and enhancing T cell reactivity to various antigens. In this regard, in vivo and in vitro research results are generally consistent. Currently, CTLA4 monoclonal antibodies are in clinical trials or have been approved for the treatment of prostate cancer, bladder cancer, colorectal cancer, gastrointestinal cancer, liver cancer, malignant melanoma, and other cancers (Grosso JF., Jure-Kunkel MN., 2013, Cancer Immun. 13:5.).
[0006] Interleukin-2 (IL-2), produced by T cells, is a growth factor that regulates T cell subsets and is a key factor in regulating immune responses. It also promotes the proliferation of activated B cells and participates in antibody responses, hematopoiesis, and tumor surveillance. Recombinant human IL-2 has been approved by the US FDA for the treatment of malignant tumors (including melanoma and renal tumors) and is currently under clinical investigation for the treatment of chronic viral infections (Chavez, AR, et al., 2009, Ann NY Acad Sci, 1182: p. 14-27). CTLA4 and CTLA4 antibodies are important factors influencing T cell function. By intervening in the immune microenvironment, CTLA4 antibodies have been shown in in vitro and in vivo studies to specifically relieve CTLA4's immunosuppression, activate T cells, and induce IL-2 production. These antibodies have broad application prospects in gene therapy for tumors and parasitic diseases.
[0007] CTLA4 antibodies can produce specific therapeutic effects on diseases and exert high efficacy, supplementing the deficiencies of traditional medications and thus opening up a new avenue for gene therapy.
[0008] Bispecific antibodies, also known as bifunctional antibodies, are specific drugs that simultaneously target two different antigens. They can be produced through immunoprecipitation and purification. Alternatively, they can be obtained through genetic engineering. Genetic engineering methods offer certain advantages due to their flexibility in optimizing binding sites, considering synthetic forms, and yield. Currently, over 45 bispecific antibodies have been identified (Dafne Müller, Kontermann R E. 2010, BioDrugs, 24(2):89-98). Many bispecific antibodies currently under development are in the IgG-scFv format, also known as the Morrison model (Coloma MJ, Morrison SL. 1997, Nat Biotechnol. 15:159-163). This format, similar to naturally occurring IgG, offers advantages in antibody engineering, expression, and purification, and has been proven to be an ideal form of bifunctional antibodies (Miller BR, Demarest SJ, et al., 2010, Protein Eng Des Sel; 23:549-57; Fitzgerald J, Lugovskoy A. 2011. MAbs; 3:299-309).
[0009] Vascular endothelial growth factor (VEGF) is a growth factor that promotes endothelial cell proliferation, angiogenesis, and vascular permeability. It binds to VEGF receptors on the cell surface and exerts its functions by activating tyrosine kinase signaling pathways. Within tumor tissue, tumor cells, tumor-invading macrophages, and mast cells secrete high levels of VEGF, which paracrine-stimulates tumor vascular endothelial cells, promoting endothelial cell proliferation and migration, inducing angiogenesis, and promoting sustained tumor growth. It also increases vascular permeability, triggers fibrin deposition in surrounding tissues, and promotes the infiltration of monocytes, fibroblasts, and endothelial cells. This facilitates tumor stroma formation and the entry of tumor cells into new blood vessels, promoting tumor metastasis. Therefore, inhibiting tumor angiogenesis is considered one of the most promising cancer treatments. The VEGF family includes VEGFA, VEGFB, VEGFC, VEGFD, and PIGF. Vascular endothelial growth factor receptors (VEGFRs) include VEGFR1 (also known as Flt1), VEGFR2 (also known as KDR or Flk1), VEGFR3 (also known as Flt4), and neuropilin-1 (NRP-1). The first three receptors are structurally similar, belonging to the tyrosine kinase superfamily. They are composed of an extracellular domain, a transmembrane segment, and an intracellular domain. The extracellular domain consists of an immunoglobulin-like domain, while the intracellular domain is a tyrosine kinase domain. VEGFR1 and VEGFR2 are primarily located on the surface of vascular endothelial cells, while VEGFR3 is primarily located on the surface of lymphatic endothelial cells.
[0010] VEGF family molecules have different affinities for several receptors. VEGFA mainly binds to VEGFR1, VEGFR2, and NRP-1 to exert its effects. VEGFR1 is the first receptor discovered. Under normal physiological conditions, the affinity of VEGFR1 for VEGFA is higher than that of VEGFR2 for VEGFA, but its intracellular tyrosinase activity is lower than that of VEGFR2 (Ma Li, Chinese Journal of Eugenics and Genetics, 24(5) (2016): 146-148).
[0011] VEGFR2 is a major regulator of angiogenesis and construction. Compared with VEGFR1, VEGFR2 has a higher tyrosine kinase activity. After binding to its ligand VEGFA, VEGFR2 mediates the proliferation and differentiation of vascular endothelial cells, as well as the formation of blood vessels and vascular permeability (Roskoski R Jr. et al., Crit Rev Oncol Hematol, 62(3)(2007):179-213.). After binding to VEGFR2, VEGFA mediates the transcriptional expression of intracellular related protein genes through the downstream PLC-γ-PKC-Raf-MEK-MAPK signaling pathway, promoting the proliferation of vascular endothelial cells (Takahashi T et al., Oncogene, 18(13)(1999):2221-2230.).
[0012] VEGFR3 is a member of the tyrosine kinase family and is primarily expressed in vascular endothelial cells during the embryonic period and lymphatic endothelial cells during adulthood. VEGFC and VEGFD bind to VEGFR3 to stimulate the proliferation and migration of lymphatic endothelial cells and promote lymphangiogenesis. NRP-1 is a non-tyrosine kinase transmembrane protein that cannot independently transduce biological signals. It can only mediate signal transduction after forming a complex with the VEGF tyrosine kinase receptor. (Ma Li, Chinese Journal of Eugenics and Genetics, 24(5)(2016): 146-148).
[0013] VEGFA and VEGFR2 are mainly involved in regulating angiogenesis. Before and after the binding of VEGFA and VEGFR2, they will trigger a cascade reaction of numerous intermediate signals in the upstream and downstream pathways, ultimately changing the physiological functions of endothelial cells in different forms such as proliferation, survival, migration, increased permeability and infiltration into surrounding tissues (Dong Hongchao et al., "Modern Oncology", Vol. 22, No. 9, September 2014, pp. 2231-3).
[0014] Many cancer patients cannot achieve long-term disease control after surgery or chemotherapy, and their 5-year survival rate remains very low. In summary, the development of less toxic, more effective treatments and combined drug therapy regimens has great clinical significance.
[0015] Summary of the Invention
[0016] After in-depth research and creative work, the inventors have surprisingly discovered that combining an anti-CTLA4-anti-PD-1 bispecific antibody with an anti-PD-1-anti-VEGFA bispecific antibody effectively inhibits tumor growth, with efficacy superior to that achieved by either the anti-VEGFA-anti-PD-1 bispecific antibody or the anti-CTLA4-anti-PD-1 bispecific antibody alone. This provides the following invention:
[0017] One aspect of the present invention relates to a pharmaceutical combination comprising an effective amount of a first bispecific antibody and an effective amount of a second bispecific antibody, wherein:
[0018] (1) A first bispecific antibody comprising:
[0019] Targeting the first protein functional region of PD-1, and
[0020] Targeting the second protein functional domain of CTLA4;
[0021] Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin;
[0022] in,
[0023] The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:30-32, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:33-35, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:36-38, respectively;
[0024] or,
[0025] The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:33-35, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:36-38, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:30-32, respectively;
[0026] (2) a second bispecific antibody comprising:
[0027] Targeting the first protein functional region of PD-1, and
[0028] Targeting the second protein functional domain of VEGFA;
[0029] Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin;
[0030] in,
[0031] The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 with amino acid sequences as shown in SEQ ID NOs:58-60, respectively, and whose light chain variable region comprises LCDR1-LCDR3 with amino acid sequences as shown in SEQ ID NOs:61-63, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 with amino acid sequences as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 with amino acid sequences as shown in SEQ ID NOs:30-32, respectively;
[0032] or,
[0033] The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs: 27-29, respectively, and its light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs: 30-32, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs: 58-60, respectively, and its light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs: 61-63, respectively.
[0034] In some embodiments of the present invention, the pharmaceutical combination, wherein:
[0035] In item (1), the immunoglobulin is of human IgG1 subtype; preferably, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations:
[0036] L234A and L235A; or
[0037] L234A and G237A; or
[0038] L235A and G237A; or
[0039] L234A, L235A and G237A.
[0040] In some embodiments of the present invention, the pharmaceutical combination, wherein:
[0041] In item (2), the immunoglobulin is of human IgG1 subtype; preferably, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations:
[0042] L234A and L235A; or
[0043] L234A and G237A; or
[0044] L235A and G237A; or
[0045] L234A, L235A and G237A.
[0046] In some embodiments of the present invention, the pharmaceutical combination, wherein:
[0047] In item (1), the immunoglobulin is of human IgG1 subtype; preferably, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations:
[0048] L234A and L235A; or
[0049] L234A and G237A; or
[0050] L235A and G237A; or
[0051] L234A, L235A, and G237A;
[0052] and
[0053] In item (2), the immunoglobulin is of human IgG1 subtype; wherein, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations:
[0054] L234A and L235A; or
[0055] L234A and G237A; or
[0056] L235A and G237A; or
[0057] L234A, L235A and G237A.
[0058] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1):
[0059] The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 14 and SEQ ID NO: 18; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 41 and SEQ ID NO: 43; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 42 and SEQ ID NO: 44;
[0060] or,
[0061] The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:6, SEQ ID NO:10, SEQ ID NO:41 and SEQ ID NO:43; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:42 and SEQ ID NO:44; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO:14 and SEQ ID NO:18; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO:16 and SEQ ID NO:20.
[0062] In some embodiments of the present invention, the pharmaceutical combination, wherein the feature of item (1) is selected from any one of the following 1) to 20):
[0063] 1)
[0064] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4;
[0065] 2)
[0066] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 8;
[0067] 3)
[0068] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 12;
[0069] 4)
[0070] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4;
[0071] 5)
[0072] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 8;
[0073] 6)
[0074] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 12;
[0075] 7)
[0076] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0077] 8)
[0078] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20;
[0079] 9)
[0080] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 8; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0081] 10)
[0082] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 8; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20;
[0083] 11)
[0084] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 12; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0085] 12)
[0086] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 12; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20;
[0087] 13)
[0088] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 41, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 42;
[0089] 14)
[0090] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44;
[0091] 15)
[0092] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 41, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 42;
[0093] 16)
[0094] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44;
[0095] 17)
[0096] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:41, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:42; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:16;
[0097] 18)
[0098] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 44; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0099] 19)
[0100] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:41, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:42; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:20;
[0101] as well as,
[0102] 20)
[0103] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:43, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:44; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:20.
[0104] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1):
[0105] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 24.
[0106] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1):
[0107] The first bispecific antibody comprises:
[0108] Targeting the first protein functional region of PD-1, and
[0109] Targeting the second protein functional domain of CTLA4;
[0110] The number of the first protein functional region is one, and the number of the second protein functional region is two;
[0111] Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody;
[0112] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 24;
[0113] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44;
[0114] The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin;
[0115] The first protein functional region and the second protein functional region are connected by a first connecting fragment; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second connecting fragment; the first connecting fragment and the second connecting fragment are the same or different;
[0116] Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 25 and SEQ ID NO: 26;
[0117] Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are both as shown in SEQ ID NO: 26.
[0118] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (2):
[0119] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from SEQ ID NO:14 and SEQ ID NO:18; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from SEQ ID NO:16, SEQ ID NO:20 and SEQ ID NO:49;
[0120] or,
[0121] The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 14 and SEQ ID NO: 18; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from SEQ ID NO: 16, SEQ ID NO: 20 and SEQ ID NO: 49; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47.
[0122] In some embodiments of the present invention, the pharmaceutical combination, wherein the feature of item (2) is selected from any one of the following 1) to 12):
[0123] 1)
[0124] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0125] 2)
[0126] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20;
[0127] 3)
[0128] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49;
[0129] 4)
[0130] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16;
[0131] 5)
[0132] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20;
[0133] 6)
[0134] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49;
[0135] 7)
[0136] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0137] 8)
[0138] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0139] 9)
[0140] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 49; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0141] 10)
[0142] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47;
[0143] 11)
[0144] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; and
[0145] 12)
[0146] The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 49; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47.
[0147] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (2):
[0148] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 54, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 56.
[0149] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (2):
[0150] The second bispecific antibody comprises:
[0151] Targeting the first protein functional region of PD-1, and
[0152] Targeting the second protein functional domain of VEGFA;
[0153] The number of the first protein functional region is one, and the number of the second protein functional region is two;
[0154] Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody;
[0155] The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 54, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 56;
[0156] The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49;
[0157] The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin;
[0158] The first protein functional region and the second protein functional region are connected by a first connecting fragment; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second connecting fragment; the first connecting fragment and the second connecting fragment are the same or different;
[0159] Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 25 and SEQ ID NO: 26;
[0160] Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are both as shown in SEQ ID NO: 26.
[0161] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1) and / or item (2):
[0162] The first protein functional region is directly connected to the second protein functional region or connected through a connecting fragment; and / or the heavy chain variable region of the single-chain antibody is directly connected to the light chain variable region of the single-chain antibody or connected through a connecting fragment.
[0163] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1) and / or item (2):
[0164] The connecting fragment is (GGGGS)n, where n is a positive integer; preferably, n is 1, 2, 3, 4, 5 or 6.
[0165] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1) and / or item (2):
[0166] The first protein functional region and the second protein functional region are independently 1, 2 or more.
[0167] In some embodiments of the present invention, the pharmaceutical combination, wherein in item (1) and / or item (2):
[0168] The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin.
[0169] In some embodiments of the present invention, the drug combination, wherein the first bispecific antibody and the second bispecific antibody are mixed together, is a pharmaceutical composition.
[0170] In some embodiments of the present invention, the pharmaceutical combination, wherein the first bispecific antibody and the second bispecific antibody are in separate packages, is a combination product.
[0171] In some embodiments of the present invention, the drug combination, wherein the mass ratio of the first bispecific antibody to the second bispecific antibody is (10:1) to (1:5), preferably (5:1) to (1:3) or (3:1) to (1:2), and more preferably 2:1.
[0172] In some embodiments of the present invention, the drug combination, wherein the molar ratio of the first bispecific antibody to the second bispecific antibody is (10:1) to (1:10), preferably (5:1) to (1:5), (3:1) to (1:3) or (2:1) to (1:2), and more preferably 1:1.
[0173] In some embodiments of the present invention, in the pharmaceutical combination, calculated based on the mass of the first bispecific antibody or the second bispecific antibody, the unit dose of the first bispecific antibody and the second bispecific antibody is independently 100 mg-2500 mg, 100 mg-2000 mg, 100 mg-1500 mg, 100 mg-1200 mg, 100 mg-1000 mg, 200 mg-800 mg, 200 mg-500 mg, 300 mg-600 mg, 400 mg-500 mg, or 450 mg.
[0174] In some embodiments of the present invention, the drug combination further comprises an effective amount of tumor chemotherapy drugs, such as alkylating agents, antimetabolites, antitumor antibiotics, plant-based anticancer drugs, hormones, immune preparations, etc.
[0175] In some embodiments of the invention, the first bispecific antibody and the second bispecific antibody are pharmaceutically active ingredients (APIs) or active ingredients.
[0176] In some embodiments of the present invention, the pharmaceutical combination consists of a first bispecific antibody, a second bispecific antibody and pharmaceutically acceptable excipients.
[0177] In some embodiments of the present invention, the first bispecific antibody, the second bispecific antibody, and the tumor chemotherapeutic drug are pharmaceutically active ingredients (APIs) or active ingredients.
[0178] In some embodiments of the present invention, the drug combination consists of a first bispecific antibody, a second bispecific antibody, a tumor chemotherapy drug, and pharmaceutically acceptable excipients.
[0179] In some embodiments of the present invention, the pharmaceutical combination further comprises one or more pharmaceutically acceptable excipients; preferably, further comprises product instructions.
[0180] Another aspect of the present invention relates to the use of any one of the drug combinations of the present invention in the preparation of a drug for treating or preventing tumors;
[0181] Preferably, the tumor is selected from one or more of pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell cancer, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma;
[0182] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer;
[0183] Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma;
[0184] Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma;
[0185] Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype:
[0186] Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
[0187] The pharmaceutical combination according to any one of the present invention is used for treating or preventing tumors;
[0188] Preferably, the tumor is selected from one or more of pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell cancer, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma;
[0189] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer;
[0190] Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma;
[0191] Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma;
[0192] Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype:
[0193] Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
[0194] Another aspect of the present invention relates to a method for treating or preventing tumors, comprising the step of administering an effective amount of the pharmaceutical combination described in any one of the present invention to a subject in need thereof;
[0195] Preferably, the tumor is selected from one or more of pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell cancer, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma;
[0196] Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer;
[0197] Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma;
[0198] Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma;
[0199] Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype:
[0200] Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
[0201] In another aspect of the present invention, it relates to a unit preparation, preferably for treating tumors, wherein the unit preparation comprises 1-10,000 mg (preferably 10-1,000 mg, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg) of the anti-CTLA4-anti-PD-1 bispecific antibody according to any aspect of the present invention and 1-10,000 mg (preferably 1-1,000 mg, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg, 200 mg or 100 mg) of the anti-PD-1-anti-VEGFA bispecific antibody according to any aspect of the present invention, and optionally one or more chemotherapeutic agents according to the present invention (such as platinum drugs and / or fluorouracil anti-tumor drugs); wherein the anti-CTLA4-anti-PD-1 bispecific antibody, the anti-PD-1-anti-VEGFA bispecific antibody and the chemotherapeutic agent are packaged separately.
[0202] The present invention relates to a method for preventing or treating cancer or tumors, wherein one or more unit preparations of the present invention are administered to a subject in need thereof. Preferably, the anti-PD-1-anti-VEGFA bispecific antibody, anti-CTLA4-anti-PD-1 bispecific antibody and chemotherapeutic agent in the unit preparation are administered separately.
[0203] In another aspect of the present invention, it relates to a single pharmaceutical dosage unit, preferably for treating tumors, comprising 0.1-10000 mg (preferably 1-1000 mg, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg, 200 mg or 100 mg) of the anti-CTLA4-anti-PD-1 bispecific antibody according to any one of the present invention and 0.1-10000 mg (preferably 1-1000 mg, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg, 200 mg or 100 mg) of the anti-PD-1-anti-VEGFA bispecific antibody according to any one of the present invention.
[0204] In one or more embodiments of the present invention, the anti-CTLA4-anti-PD-1 bispecific antibody, the VEGFA-anti-PD-1 bispecific antibody and / or the chemotherapeutic drug are in a form suitable for intravenous injection or intravenous drip, preferably in liquid form.
[0205] In one or more embodiments of the present invention, the step of administering to the subject an effective amount of the anti-CTLA4-anti-PD-1 bispecific antibody according to any one of the present invention and / or the anti-PD-1-anti-VEGFA bispecific antibody according to any one of the present invention is before or after surgical treatment, and / or before or after radiotherapy.
[0206] In one or more embodiments of the present invention, the single administration dose of the anti-CTLA4-anti-PD-1 bispecific antibody according to any one of the present invention and / or the anti-PD-1-anti-VEGFA bispecific antibody according to any one of the present invention is 0.1-100 mg per kilogram of body weight, preferably 1-10 mg; or the single administration dose of the anti-CTLA4-anti-PD-1 bispecific antibody according to any one of the present invention and / or the anti-PD-1-anti-VEGFA bispecific antibody according to any one of the present invention is 10-1000 mg per subject, preferably 50-500 mg, 100-400 mg, 150-300 mg, 150-250 mg or 200 mg.
[0207] Preferably, the dosage is from twice a day to about every other day, or once every 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks or 6 weeks;
[0208] Preferably, the administration method is intravenous drip, intravenous injection, subcutaneous injection or intraperitoneal injection.
[0209] MSI (microsatellite instability) stands for microsatellite instability. Microsatellites are short tandem repeats found throughout the human genome, consisting of single, double, or high-order nucleotide repeats, with a frequency of 10-50 repeats. Compared to normal cells, certain abnormal tissue cells, such as tumors, exhibit altered microsatellite lengths due to insertions or deletions of repeat units. This is called MSI. Based on the degree of MSI instability, these types can be categorized as microsatellite instability-high (MSI-H), microsatellite instability-low (MSI-L), and microsatellite stable (MSS). The primary cause of MSI is a defect in DNA mismatch repair (MMR). Human mismatch repair genes (MMR) are transcribed and translated to produce corresponding mismatch repair proteins. Loss of expression of any of these MMR proteins can lead to a defect in mismatch repair, resulting in a loss of the ability to repair base mismatches during DNA replication and an accumulation of these mismatches, leading to microsatellite instability (MSI). Approximately 15% of colorectal cancers are caused by MSI. It was first discovered in colorectal cancer and can also occur in gastric cancer, endometrial cancer, adrenal cortical tumors, etc. (Baretti M et al. Pharmacol Ther. 2018; 189: 45-62.). Subsequent studies have also found MSI-H / dMMR characteristics in mesothelioma, sarcoma, adrenal cortical carcinoma, malignant melanoma, and ovarian germ cell tumors.
[0210] MSI-H and dMMR represent the results produced by two different detection methods. dMMR and MSI-H are biologically consistent and are called MSI-H / dMMR or MSI-high / dMMR. MSI-L and MSS are phenotypes of proficient mismatch repair (pMMR). The dMMR detection method is based on the immunohistochemical protein detection of the four mismatch genes MSH2, MLH1, MSH6 and PMS2 in tumor specimens (including surgical specimens and puncture specimens). If any of the four proteins is expressed absent, it is dMMR; if all four proteins are positively expressed, the tumor is pMMR, which means that the mismatch repair function is intact. The MSI test is a one-to-one pairing test of the length of the repetitive DNA sequence (microsatellite sequence) of tumor cells and somatic cells, and the length is compared. When using PCR to test five standard loci based on the US NCI standard, if two or more loci are discordant, it is considered unstable and defined as MSI-H. If one locus is discordant, it is called MSI-L (microsatellite instability, low level). If all five loci are consistent, it is MSS. High-throughput sequencing (also known as next-generation sequencing technology, NGS) can also be used to detect microsatellite instability. When a larger number of microsatellite loci, such as more than five or a number of other microsatellite loci, are used for PCR testing, discordance of ≥30% of the loci is generally considered MSI-H, while consistency at all loci is defined as MSS, and between 0 and 30% is defined as MSI-L.
[0211] In one or more embodiments of the present invention, the bispecific antibody is in the form of IgG-scFv, namely the Morrison model.
[0212] In one or more embodiments of the present invention, the bispecific antibody comprises a single-chain antibody linked to the C-terminus of an immunoglobulin heavy chain. Since immunoglobulins consist of two heavy chains, two single-chain antibody molecules are linked to one immunoglobulin molecule. Preferably, the two single-chain antibody molecules are identical. Preferably, the single-chain antibody is linked to the C-terminus of the immunoglobulin heavy chain via an amide bond formed by the aforementioned linker fragment.
[0213] In one or more embodiments of the present invention, the constant region of the immunoglobulin is humanized, for example, the heavy chain constant region adopts Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region adopts Ig kappa chain C region, ACCESSION: P01834.
[0214] In one or more embodiments of the present invention, the bispecific antibody is a monoclonal antibody.
[0215] In one or more embodiments of the present invention, the bispecific antibody is a humanized antibody.
[0216] Antibody therapeutics, particularly monoclonal antibodies (mABs), have demonstrated promising therapeutic effects in the treatment of a wide range of diseases. Traditional experimental approaches to obtaining these therapeutic antibodies involve immunizing animals with antigens to generate antibodies that target the antigen, or improving antibodies with low affinity for the antigen through affinity maturation.
[0217] The variable regions of the light and heavy chains determine antigen binding; the variable region of each chain contains three hypervariable regions, called complementarity determining regions (CDRs) (the CDRs of the heavy chain (H) include HCDR1, HCDR2, and HCDR3, and the CDRs of the light chain (L) include LCDR1, LCDR2, and LCDR3; they were named by Kabat et al., see Sequences of Proteins of Immunological Interest, Fifth Edition (1991), Volumes 1-3, NIH Publication 91-3242, Bethesda, Md).
[0218] The amino acid sequences of the CDR regions of the monoclonal antibody sequences in items (1) to (7) below were analyzed using techniques well known to those skilled in the art. The results are as follows:
[0219] (1)14C12
[0220] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 16.
[0221] The amino acid sequences of the three CDR regions of its heavy chain variable region are as follows:
[0222] HCDR1: GFAFSSYD (SEQ ID NO: 27)
[0223] HCDR2: ISGGGRYT (SEQ ID NO: 28)
[0224] HCDR3:ANRYGEAWFAY(SEQ ID NO:29)
[0225] The amino acid sequences of the three CDR regions of its light chain variable region are as follows:
[0226] LCDR1:QDINTY (SEQ ID NO: 30)
[0227] LCDR2:RAN (SEQ ID NO:31)
[0228] LCDR3:LQYDEFPLT (SEQ ID NO:32)
[0229] (2)14C12H1L1
[0230] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 20.
[0231] The amino acid sequences of the three CDR regions of its heavy chain variable region are identical to those of 14C12.
[0232] The amino acid sequences of the three CDR regions of its light chain variable region are identical to those of 14C12.
[0233] (3)14C12H1L1(M)
[0234] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 49.
[0235] The amino acid sequences of the three CDR regions of its heavy chain variable region are identical to those of 14C12.
[0236] The amino acid sequences of the three CDR regions of its light chain variable region are identical to those of 14C12.
[0237] (4)4G10
[0238] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 4;
[0239] The amino acid sequences of the three CDR regions of its heavy chain variable region are as follows:
[0240] HCDR1: GYSFTGYT (SEQ ID NO: 33)
[0241] HCDR2: INPYNNIT (SEQ ID NO: 34)
[0242] HCDR3: ARLDYRSY (SEQ ID NO: 35)
[0243] The amino acid sequences of the three CDR regions of its light chain variable region are as follows:
[0244] LCDR1:TGAVTTSNF (SEQ ID NO:36)
[0245] LCDR2:GTN (SEQ ID NO:37)
[0246] LCDR3:ALWYSNHWV (SEQ ID NO:38)
[0247] (5)4G10H1L1
[0248] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 8;
[0249] The amino acid sequences of the three CDR regions of its heavy chain variable region are identical to those of 4G10.
[0250] The amino acid sequences of the three CDR regions of its light chain variable region are identical to those of 4G10.
[0251] (6)4G10H3L3
[0252] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO: 12;
[0253] The amino acid sequences of the three CDR regions of its heavy chain variable region are identical to those of 4G10.
[0254] The amino acid sequences of the three CDR regions of its light chain variable region are identical to those of 4G10.
[0255] (7) Bevacizumab
[0256] The amino acid sequence of the heavy chain variable region is shown in SEQ ID NO:45, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:47;
[0257] The amino acid sequences of the three CDR regions of its heavy chain variable region are as follows:
[0258] HCDR1: GYTFTNYG (SEQ ID NO: 58)
[0259] HCDR2: INTYTGEP (SEQ ID NO: 59)
[0260] HCDR3:AKYPHYYGSSHWYFDV(SEQ ID NO:60)
[0261] The amino acid sequences of the three CDR regions of its heavy chain variable region are as follows:
[0262] LCDR1:QDISNY (SEQ ID NO:61)
[0263] LCDR2:FTS (SEQ ID NO:62)
[0264] LCDR3:QQYSTVPWT (SEQ ID NO:63)
[0265] Unless otherwise indicated, scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. Furthermore, the laboratory procedures for cell culture, molecular genetics, nucleic acid chemistry, and immunology used herein are conventional procedures widely used in the relevant fields. To facilitate a better understanding of the present invention, definitions and explanations of relevant terms are provided below.
[0266] As used herein, when referring to the amino acid sequence of the CTLA4 protein (Cytotoxic T-Lymphocyte-associated Antigen 4), it includes the full length of the CTLA4 protein, or the extracellular fragment CTLA4 ECD of CTLA4 or a fragment containing CTLA4 ECD; it also includes a fusion protein of CTLA4 ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally produced or artificially introduced into the amino acid sequence of the CTLA4 protein without affecting its biological function. Therefore, in the present invention, the term "CTLA4 protein" should include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of the CTLA4 protein, it also includes the corresponding sequence fragments in its natural or artificial variants.
[0267] As used herein, when referring to the amino acid sequence of the PD-1 protein (NCBI GenBank: NM_005018), it includes the full length of the PD-1 protein, or the extracellular fragment PD-1ECD or a fragment containing the PD-1ECD; it also includes a fusion protein of the PD-1ECD, such as a fragment fused with the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally or artificially introduced into the amino acid sequence of the PD-1 protein without affecting its biological function. Therefore, in the present invention, the term "addition), protein" should include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of the PD-1 protein, it also includes the corresponding sequence fragments in its natural or artificial variants.
[0268] As used herein, unless otherwise specified, B7 refers to B7-1 and / or B7-2. The specific protein sequences are known in the art and can be found in existing literature or GenBank. For example, B7-1 (CD80, NCBI Gene ID: 941) and B7-2 (CD86, NCBI Gene ID: 942).
[0269] As used herein, when referring to the amino acid sequence of the VEGFA protein (GenBank ID: NP_001165097.1), it includes the full length of the VEGFA protein, and also includes fusion proteins of VEGFA, such as fragments fused to the Fc protein fragment of mouse or human IgG (mFc or hFc). However, those skilled in the art understand that mutations or variations (including but not limited to substitutions, deletions and / or additions) can occur naturally or be artificially introduced into the amino acid sequence of the VEGFA protein without affecting its biological function. Therefore, in the present invention, the term "VEGFA protein" should include all such sequences, including natural or artificial variants thereof. Furthermore, when describing a sequence fragment of the VEGFA protein, it also includes the corresponding sequence fragments in its natural or artificial variants.
[0270] As used herein, when referring to the amino acid sequence of VEGFR2 protein (also known as KDR, GenBank ID: NP_002244), it includes the full length of the VEGFR2 protein, or the extracellular fragment VEGFR2-ECD of VEGFR2 or a fragment comprising VEGFR2-ECD; it also includes a fusion protein of VEGFR2-ECD, for example, a fragment fused to the Fc protein fragment (mFc or hFc) of mouse or human IgG. However, it is understood by those skilled in the art that mutations or variations (including but not limited to substitutions, deletions and / or additions) can be naturally produced or artificially introduced into the amino acid sequence of the VEGFR2 protein without affecting its biological function. Therefore, in the present invention, the term "VEGFR2 protein" should include all such sequences, including its natural or artificial variants. Furthermore, when describing a sequence fragment of the VEGFR2 protein, it also includes the corresponding sequence fragments in its natural or artificial variants.
[0271] As used herein, unless otherwise specified, the VEGFRs are VEGFR1 and / or VEGFR2; their specific protein sequences are known in the art and can be found in existing literature or GenBank. For example, VEGFR1 (VEGFR1, NCBI Gene ID: 2321) and VEGFR2 (VEGFR2, NCBI Gene ID: 3791).
[0272] As used herein, the term EC 50 It refers to the concentration for 50% of maximal effect, which is the concentration that can cause 50% of the maximum effect.
[0273] As used herein, the term "antibody" refers to an immunoglobulin molecule that is typically composed of two pairs of polypeptide chains, each pair having a "light" (L) chain and a "heavy" (H) chain. In a general sense, the heavy chain can be understood as the polypeptide chain with the larger molecular weight in the antibody, and the light chain refers to the polypeptide chain with the smaller molecular weight in the antibody. Light chains can be classified as κ and λ light chains. Heavy chains are typically classified as μ, δ, γ, α or ε, and define the isotype of the antibody as IgM, IgD, IgG, IgA and IgE, respectively. Within the light and heavy chains, the variable and constant regions are connected by a "amino acid region" of about 12 or more amino acids, and the heavy chain also contains a "amino acid region" of about 3 or more amino acids. Each heavy chain consists of a heavy chain variable region (V H ) and heavy chain constant region (C H ). The heavy chain constant region consists of three domains (C H1 、C H2 and C H3 Each light chain consists of a light chain variable region (V L ) and the light chain constant region (C L ). The light chain constant region consists of a domain C L The constant region of the antibody mediates the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. H and V L The V domains can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FRs). H and V L It consists of three CDRs and four FRs arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable region (V H and V L) respectively form antibody binding sites. The allocation of amino acids to each region or domain follows the definition of Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda, Md. (1987and 1991)), or Chothia & Lesk (1987) J. Mol. Biol. 196: 901-917; Chothia et al. (1989) Nature 342: 878-883. In particular, the heavy chain can also contain more than 3 CDRs, such as 6, 9, or 12. For example, in the bifunctional antibody of the present invention, the heavy chain can be the C-terminus of the heavy chain of an IgG antibody connected to the scFv of another antibody, in which case the heavy chain contains 9 CDRs. The term "antibody" is not limited to any particular method for producing antibodies. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies. The antibodies can be of different isotypes, for example, IgG (eg, IgG1, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
[0274] Antibody antigen-binding fragments (e.g., those described above) can be obtained from a given antibody using conventional techniques known to those skilled in the art (e.g., recombinant DNA techniques or enzymatic or chemical cleavage methods) and screened for specificity in the same manner as for intact antibodies.
[0275] Herein, unless the context clearly indicates otherwise, when referring to the term "antibody", it includes not only intact antibodies, but also antigen-binding fragments of antibodies.
[0276] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" refer to an antibody or an antibody fragment from a group of highly homologous antibody molecules, that is, a group of identical antibody molecules except for possible spontaneous natural mutations. Monoclonal antibodies have high specificity for a single epitope on an antigen. Polyclonal antibodies are relative to monoclonal antibodies and generally contain at least two or more different antibodies, which generally recognize different epitopes on an antigen. Monoclonal antibodies can generally be obtained using the hybridoma technology first reported by Kohler et al. (Kohler et al., Nature, 256:495, 1975), but can also be obtained using recombinant DNA technology (see, for example, US Patent 4,816,567).
[0277] As used herein, the term "humanized antibody" refers to an antibody or antibody fragment obtained by replacing all or part of the CDR region of a human immunoglobulin (recipient antibody) with the CDR region of a non-human antibody (donor antibody), wherein the donor antibody can be a non-human (e.g., mouse, rat, or rabbit) antibody with the desired specificity, affinity, or reactivity. In addition, some amino acid residues in the framework region (FR) of the recipient antibody can also be replaced with amino acid residues of the corresponding non-human antibody, or with amino acid residues of other antibodies, to further improve or optimize the performance of the antibody. For more details on humanized antibodies, see, for example, Jones et al., Nature, 321: 522 525 (1986); Reichmann et al., Nature, 332: 323 329 (1988); Presta, Curr. Op. Struct. Biol., 2: 593 596 (1992); and Clark, Immunol. Today 21: 397 402 (2000).
[0278] As used herein, the term "epitope" refers to the site on an antigen that is specifically bound by an immunoglobulin or antibody. "Epitope" is also referred to as an "antigenic determinant" in the art. An epitope or antigenic determinant is typically composed of chemically active surface groups of a molecule, such as amino acids or carbohydrates or sugar side chains, and typically has specific three-dimensional structural characteristics and specific charge characteristics. For example, an epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 continuous or non-continuous amino acids in a unique spatial conformation, which can be "linear" or "conformational." See, for example, Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G.E. Morris, Ed. (1996). In a linear epitope, all interacting points between a protein and an interacting molecule (e.g., an antibody) exist linearly along the primary amino acid sequence of the protein. In a conformational epitope, the interacting points exist across separate protein amino acid residues.
[0279] As used herein, the term "isolated" or "isolated" refers to something that is obtained artificially from its natural state. If a substance or component is "isolated" in nature, it may be that its natural environment has been changed, or that the substance has been separated from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and a highly pure identical polynucleotide or polypeptide isolated from this natural state is called isolated. The term "isolated" or "isolated" does not exclude the presence of artificial or synthetic substances, nor does it exclude the presence of other impure substances that do not affect the activity of the substance.
[0280] As used herein, the term "E. coli expression system" refers to an expression system consisting of E. coli (strain) and a vector, wherein the E. coli (strain) is derived from commercially available strains, such as but not limited to: GI698, ER2566, BL21 (DE3), B834 (DE3), BLR (DE3).
[0281] As used herein, the term "vector" refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector is capable of expressing a protein encoded by the inserted polynucleotide, it is referred to as an expression vector. A vector can be introduced into a host cell via transformation, transduction, or transfection, allowing the genetic material it carries to be expressed in the host cell. Vectors are well known to those skilled in the art and include, but are not limited to, plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), or P1-derived artificial chromosomes (PACs); bacteriophages, such as lambda phage or M13 phage, and animal viruses. Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomas (such as SV40). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and reporter genes. Additionally, a vector may contain an origin of replication.
[0282] As used herein, the term "host cell" refers to a cell that can be used to introduce a vector, including but not limited to prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, BHK cells, HEK 293 cells or human cells.
[0283] As used herein, the term "specific binding" refers to a non-random binding reaction between two molecules, such as an antibody and its antigen. In certain embodiments, an antibody that specifically binds to an antigen (or has specificity for an antigen) means that the antibody binds to the antigen with a specificity of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 Affinity of M or less (K D In some embodiments of the present invention, the term "targeting" refers to specific binding.
[0284] As used herein, the term "K D " refers to the dissociation equilibrium constant of a specific antibody-antigen interaction, which is used to describe the binding affinity between the antibody and the antigen. The smaller the equilibrium dissociation constant, the tighter the antibody-antigen binding and the higher the affinity between the antibody and the antigen. Generally, antibodies bind with a dissociation equilibrium constant of less than about 10 -5 M, for example, less than about 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 M or less dissociation equilibrium constant (K D ) binding to the antigen, e.g., as measured using surface plasmon resonance (SPR) in a BIACORE instrument, or by a Fortebio Octet molecular interaction instrument.
[0285] As used herein, the terms "monoclonal antibody" and "monoclonal antibody" have the same meaning and are used interchangeably; the terms "polyclonal antibody" and "polyclonal antibody" have the same meaning and are used interchangeably; the terms "polypeptide" and "protein" have the same meaning and are used interchangeably. Furthermore, in the present invention, amino acids are generally represented by single-letter and three-letter abbreviations known in the art. For example, alanine can be represented by A or Ala.
[0286] As used herein, the term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier and / or excipient" refers to a carrier and / or excipient that is pharmacologically and / or physiologically compatible with the subject and the active ingredient, which is well known in the art (see, for example, Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995), and includes, but is not limited to, pH adjusters, surfactants, adjuvants, and ionic strength enhancers. For example, pH adjusters include, but are not limited to, phosphate buffers; surfactants include, but are not limited to, cationic, anionic, or nonionic surfactants, such as Tween-80; and ionic strength enhancers include, but are not limited to, sodium chloride.
[0287] As used herein, the term "adjuvant" refers to a nonspecific immunopotentiator that, when delivered to the body together with an antigen or in advance, can enhance the body's immune response to the antigen or change the type of immune response. There are many types of adjuvants, including but not limited to aluminum adjuvants (such as aluminum hydroxide), Freund's adjuvants (such as complete Freund's adjuvant and incomplete Freund's adjuvant), Corynebacterium brevis, lipopolysaccharide, cytokines, etc. Freund's adjuvant is the most commonly used adjuvant in animal experiments. Aluminum hydroxide adjuvant is more commonly used in clinical trials.
[0288] As used herein, the term "effective amount" refers to an amount sufficient to obtain or at least partially obtain the desired effect. For example, an effective amount for preventing a disease (e.g., a disease associated with CTLA4 binding to B7 or excessive CTLA4 activity, such as a tumor) refers to an amount sufficient to prevent, stop, or delay the occurrence of a disease (e.g., a disease associated with CTLA4 binding to B7 or excessive CTLA4 activity, such as a tumor); an effective amount for treating a disease refers to an amount sufficient to cure or at least partially stop the disease and its complications in a patient already suffering from the disease. Determining such an effective amount is entirely within the capabilities of those skilled in the art. For example, an effective amount for therapeutic use will depend on the severity of the disease to be treated, the overall state of the patient's own immune system, the patient's general condition, such as age, weight and sex, the mode of administration of the drug, and other treatments administered simultaneously, etc.
[0289] A "recurrent" cancer is one that grows back in the original site or at a distant site after responding to initial treatment (such as surgery). A "locally recurrent" cancer is one that appears after treatment in the same location as a previously treated cancer.
[0290] "Metastatic" cancer is cancer that has spread from one part of the body (such as the lungs) to another part of the body.
[0291] As used herein, the term "completely eliminated" refers to the absence of a binding signal or an extremely low binding signal as detected by existing instrumentation (e.g., the Fortebio Octet molecular interaction instrument). In one embodiment of the present invention, the absence of a binding signal or an extremely low binding signal refers to a binding signal (i.e., a response value or Response) of less than 0.1 nm.
[0292] In the present invention, unless otherwise specified, the "first" (e.g., the first bispecific antibody, the first protein functional domain, or the first connecting fragment) and the "second" (e.g., the second bispecific antibody, the second protein functional domain, or the second connecting fragment) are for the purpose of distinguishing between references or clarifying the expression, and do not have a typical order meaning.
[0293] In the present invention, unless otherwise specified, "about" or "approximately" means fluctuating within a range of 10%, 20% or 30% of the modified numerical value or physical quantity, for example, about 100 minutes or about 100 minutes can be 90 minutes to 110 minutes, 80 minutes to 120 minutes or 70 minutes to 130 minutes.
[0294] The entire contents of the prior Chinese patent publications CN112300286A and CN112830972A are hereby incorporated by reference into the present application.
[0295] Advantageous Effects of the Invention
[0296] The present invention achieves one or more of the following technical effects (1) to (2):
[0297] (1) The drug combination of the present invention can effectively prevent or treat tumors.
[0298] (2) The combination of anti-CTLA4-anti-PD-1 bispecific antibody and anti-PD-1-anti-VEGFA bispecific antibody has a pharmacological effect of effectively inhibiting tumor growth, and the effect is better than that of anti-PD-1-anti-VEGFA bispecific antibody alone or anti-CTLA4-anti-PD-1 bispecific antibody alone, achieving a synergistic technical effect. BRIEF DESCRIPTION OF THE DRAWINGS
[0299] Figure 1: Effect of the combination of anti-CTLA4-anti-PD-1 bispecific antibody and anti-PD-1-anti-VEGFA bispecific antibody on the secretion of cytokine IL-2 induced by stimulated mixed culture of PBMCs and Raji-PDL1 cells.
[0300] Figure 2: Mixed lymphocyte reaction detection of anti-CTLA4-anti-PD-1 bispecific antibody combined with anti-PD-1-anti-VEGFA bispecific antibody promoting cytokine IFN-γ secretion. DETAILED DESCRIPTION
[0301] The embodiments of the present invention will be described in detail below with reference to the examples. Those skilled in the art will appreciate that the following examples are only intended to illustrate the present invention and should not be construed as limiting the scope of the present invention. Specific techniques or conditions not specified in the examples are based on the techniques or conditions described in the literature in this area (e.g., with reference to "Molecular Cloning Experiment Guide" by J. Sambrook et al., translated by Huang Peitang et al., 3rd edition, Science Press) or product specifications. Reagents or instruments not specified by manufacturer are conventional products that can be purchased commercially.
[0302] In the following embodiments of the present invention:
[0303] Human peripheral blood mononuclear cells were isolated and prepared by Zhongshan Kangfang Biopharmaceutical Co., Ltd. with the informed consent of the providers.
[0304] Raji-PDL1 is a cell expressing human PD-L1 constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd. based on the human B cell line Raji cells through transfection.
[0305] Ficoll-Paque TM PLUS (or Ficoll-Paque PLUS) was purchased from GE Healthcare, catalog number: 17-1440-02.
[0306] Human IL-2 ELISA Kit was purchased from Dakoway Biotechnology Co., Ltd., catalog number: 1110202.
[0307] RPMI 1640 medium, DMEM medium, Trypsin-EDTA (0.25%) phenol red, and Blasticidin were all from Gibco.
[0308] Staphylococcus aureus enterotoxin antigen (SEB) was from Denotec, product number: BT202.
[0309] FBS was from Excell bio, product number: FSP500.
[0310] Mitomycin C (MMC) was obtained from Stressmarq, product number: SIH-246-10MG, batch number: SM286474.
[0311] The sequence of the isotype control antibody is human anti-hen egg lysozyme IgG (i.e., anti-HEL antibody, or human IgG, abbreviated as hIgG). The sequence is derived from the variable region sequence of the Fab F10.6.6 sequence in the Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies published by Acierno et al. (Acierno et al. J Mol Biol. 2007; 374(1): 130-146). The hIgG1DM used in the examples is an isotype control antibody with the hG1DM constant region sequence for anti-HEL, prepared in the laboratory of Zhongshan Kangfang Biopharmaceutical Co., Ltd., batch number: 20190520.
[0312] Preparation Example 1: Sequence Design of Anti-CTLA4 Antibody
[0313] The amino acid sequences of the heavy and light chains of the anti-CTLA4 antibody 4G10 and its humanized antibodies 4G10H1L1 and 4G10H3L3, as well as the encoding nucleic acid sequences are identical to those of 4G10, 4G10H1L1, and 4G10H3L3 in Chinese Patent Publication CN 106967172A, respectively.
[0314] (1) 4G10 heavy chain variable region sequence and light chain variable region sequence
[0315] Nucleic acid sequence of heavy chain variable region: (372bp)
[0316] The amino acid sequence it encodes is: (124aa)
[0317] Nucleic acid sequence of light chain variable region: (378 bp)
[0318] The amino acid sequence it encodes is: (126aa)
[0319] (2) Heavy chain variable region sequence and light chain variable region sequence of humanized monoclonal antibody 4G10H1L1
[0320] Nucleic acid sequence of heavy chain variable region (4G10H1V): (345 bp)
[0321] The amino acid sequence it encodes is: (115aa)
[0322] Nucleic acid sequence of light chain variable region (4G10L1V): (327 bp)
[0323] The amino acid sequence it encodes is: (109aa)
[0324] (3) Heavy chain variable region sequence and light chain variable region sequence of humanized monoclonal antibody 4G10H3L3
[0325] Nucleic acid sequence of heavy chain variable region (4G10H3V): (345 bp)
[0326] The amino acid sequence it encodes (4G10H3V): (115aa)
[0327] Nucleic acid sequence of light chain variable region (4G10L3V): (327 bp)
[0328] The amino acid sequence it encodes (4G10L3V): (109aa)
[0329] Preparation Example 2: Sequence Design of Anti-PD-1 Antibody 14C12 and Its Humanized Antibody 14C12H1L1
[0330] The amino acid sequences of the heavy and light chains of the anti-PD-1 antibody 14C12 and its humanized antibody 14C12H1L1, as well as the encoding nucleic acid sequences, are identical to those of 14C12 and 14C12H1L1 in Chinese Patent Publication CN106967172A, respectively.
[0331] (1) Heavy chain variable region sequence and light chain variable region sequence of 14C12
[0332] Nucleic acid sequence of heavy chain variable region: (354 bp)
[0333] The amino acid sequence it encodes is: (118aa)
[0334] Nucleic acid sequence of light chain variable region: (321 bp)
[0335] The amino acid sequence it encodes is: (107aa)
[0336] (2) Heavy chain variable region sequence, light chain variable region sequence, heavy chain sequence, and light chain sequence of humanized monoclonal antibody 14C12H1L1
[0337] Nucleic acid sequence of heavy chain variable region: (354 bp)
[0338] The amino acid sequence it encodes is: (118aa)
[0339] Nucleic acid sequence of light chain variable region: (321 bp)
[0340] The amino acid sequence it encodes is: (107aa)
[0341] DNA sequence of 14C12H1L1 heavy chain (14C12H1): (1344 bp)
[0342] The amino acid sequence it encodes is: (448aa)
[0343] DNA sequence of 14C12H1L1 light chain (14C12L1): (642 bp)
[0344] The amino acid sequence it encodes is: (214aa)
[0345] Preparation Example 3: Sequence Design of Bifunctional Antibodies BiAb001(M), BiAb002(M), BiAb003(M) and BiAb004(M)
[0346] The structural model of the bifunctional antibodies BiAb001(M), BiAb002(M), BiAb003(M), and BiAb004(M) belongs to the Morrison model (IgG-scFv), that is, the C-termini of the two heavy chains of an IgG antibody are connected to the scFv fragment of another antibody through a linker fragment. The design composition of their heavy and light chains is shown in Table A below.
[0347] Table A: Sequence design of BiAb001(M), BiAb002(M), BiAb003(M) and BiAb004(M)
[0348] In Table A above:
[0349] The amino acid sequence of Linker1 is (GGGGS)3 (SEQ ID NO: 25)
[0350] The amino acid sequence of Linker2 is (GGGGS)4 (SEQ ID NO: 26)
[0351] In addition, in Table A above, 4G10H1V(M), 4G10L1V(M), 4G10H3V(M), and 4G10L3V(M) in the scFv fragments of the BiAb001(M), BiAb002(M), BiAb003(M), and BiAb004(M) antibodies are mutated based on 4G10H1V, 4G10L1V, 4G10H3V, and 4G10L3V, respectively, in their framework regions, effectively optimizing the structure of the antibodies and improving their effectiveness.
[0352] (1) 4G10H1V(M): (115aa, the amino acid sequence mutation sites based on 4G10H1V are underlined)
[0353] (2) 4G10L1V(M): (110aa, the amino acid sequence mutation sites based on 4G10L1V are underlined)
[0354] (3) 4G10H3V(M): (115aa, the amino acid sequence mutation sites based on 4G10H3V are underlined)
[0355] (4) 4G10L3V(M): (110aa, the amino acid sequence mutation sites based on 4G10L3V are underlined)
[0356] To distinguish it from the mutated antibodies described below, BiAb004(M) is also referred to as BiAb004(hG1WT) in the examples herein. BiAb004(M) is a "wild-type" antibody, employing the Ig gamma-1 chain C region, ACCESSION: P01857, as the heavy chain constant region and the Ig kappa chain C region, ACCESSION: P01834, as the light chain constant region.
[0357] Preparation Example 4: Design of amino acid mutations in the non-variable region of humanized bifunctional antibody BiAb004
[0358] Based on BiAb004 (hG1WT) obtained in Preparation Example 3, the present inventors obtained BiAb004 (hG1TM) by introducing a point mutation from leucine to alanine (L234A) at position 234 of its heavy chain, a point mutation from leucine to alanine (L235A) at position 235, and a point mutation from glycine to alanine (G237A) at position 237.
[0359] DNA sequence of the heavy chain of the immunoglobulin portion of BiAb004 (hG1™): (1344 bp, the mutation site is underlined)
[0360] Amino acid sequence of the heavy chain of the immunoglobulin portion of BiAb004 (hG1™): (448 aa, the mutation site is underlined)
[0361] The DNA sequences of the light chains of BiAb004 (hG1TM) and BiAb004 (hG1WT) are identical, and the amino acid sequences they encode are also identical. For the specific sequences, see Preparation Example 3.
[0362] Preparation Example 5: Preparation of anti-VEGFA antibody Bevacizumab
[0363] The amino acid sequences of the heavy and light chain variable regions of the marketed anti-VEGFA monoclonal antibody Avastin (Bevacizumab) were referenced in Chinese Patent Publication CN1259962A. The nucleic acid sequences encoding the heavy and light chain variable regions were synthesized by GenScript.
[0364] Amino acid sequence of Bevacizumab heavy chain variable region (Bevacizumab-Hv): (123aa)
[0365] Nucleic acid sequence encoding the Bevacizumab heavy chain variable region: (369 bp)
[0366] Amino acid sequence of the light chain variable region of Bevacizumab (Bevacizumab-Lv): (107aa)
[0367] Nucleic acid sequence encoding the Bevacizumab light chain variable region: (321 bp)
[0368] The heavy chain constant region all used Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region all used Ig kappa chain C region, ACCESSION: P01834.
[0369] The heavy and light chain cDNAs of bevacizumab were cloned into the pcDNA3.1 vector to generate recombinant expression plasmids for the antibody bevacizumab. The recombinant plasmids were transfected into 293F cells. The 293F cell culture fluid was purified and then tested.
[0370] The anti-VEGFA monoclonal antibody Avastin (Bevacizumab) was produced.
[0371] Preparation Example 6: Sequence Design of Mutant 14C12H1L1(M) of Anti-PD-1 Humanized Antibody 14C12H1L1
[0372] Based on 14C12H1L1, individual amino acids in its framework region (light chain) were mutated to obtain 14C12H1L1(M).
[0373] Heavy chain variable region of 14C12H1L1(M):
[0374] The heavy chain variable region 14C12H1 is identical to that of 14C12H1L1, i.e., the amino acid sequence is shown in SEQ ID NO:18.
[0375] Light chain variable region of 14C12H1L1(M): (108 aa, amino acid sequence mutation sites based on 14C12H1L1 are underlined)
[0376] Preparation Example 7: Sequence Design of Bispecific Antibodies
[0377] 1. Sequence Design
[0378] The structural model of the bispecific antibody of the present invention belongs to the Morrison model (IgG-scFv), that is, the C-termini of the two heavy chains of an IgG antibody are connected to the scFv fragment of another antibody, and the main components of the heavy chain and light chain are designed as shown in Table B below.
[0379] Based on the aforementioned bevacizumab, the VP101 antibody, named VP101(M), utilizes the amino acid sequences of the heavy and light chain variable regions of 14C12H1L1(M) as the scFv fragment. Compared to 14C12H1L1, 14C12H1L1(M) effectively optimizes the bispecific antibody structure and enhances its effectiveness.
[0380] Table B: Composition design of heavy and light chains of VP101(M) and VP101(G4M)
[0381] In Table B above:
[0382] (1) The "V" in the lower right corner refers to the variable region of the corresponding heavy chain or the variable region of the corresponding light chain. If "V" is not marked, the corresponding heavy chain or light chain is the full length including the constant region. The amino acid sequences of these variable regions or full lengths and their encoding nucleic acid sequences are referenced to the corresponding sequences described in the preparation examples above.
[0383] (2) The amino acid sequence of Linker2 is: GGGGSGGGGSGGGGSG GGGS (SEQ ID NO: 26)
[0384] Alternatively, the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO: 25) can be used as Linker 1 to replace the aforementioned Linker 2.
[0385] (3) Bevacizumab-H uses the Ig gamma-1 chain C region, ACCESSION: P01857 as the heavy chain constant region.
[0386] (4) Bevacizumab-G4H uses Ig gamma-4 chain C region, ACCESSION: P01861.1 as the heavy chain constant region.
[0387] 2. Expression and Purification of Antibody VP101(M)
[0388] The heavy chain cDNA sequence and light chain cDNA sequence of VP101(M) were cloned into pUC57simple (provided by GenScript) vector to obtain pUC57simple-VP101H and pUC57simple-VP101L plasmids, respectively.
[0389] Plasmids pUC57simple-VP101H and pUC57simple-VP101L were digested with HindIII and EcoRI, and the heavy and light chains recovered by electrophoresis were subcloned into the pcDNA3.1 vector. The recombinant plasmids were extracted and co-transfected into 293F cells. After 7 days of cell culture, the culture medium was centrifuged at high speed, the supernatant was concentrated, and then loaded onto a HiTrap MabSelect SuRe column. The protein was eluted in one step with Elution Buffer to recover the target antibody VP101, and the buffer was exchanged with PBS.
[0390] 3. Detection of Antibody VP101(M)
[0391] The purified samples were added into reduced protein electrophoresis loading buffer and non-reduced protein electrophoresis loading buffer respectively, boiled and then subjected to SDS-PAGE electrophoresis detection.
[0392] To distinguish it from the mutated antibody described in Preparation Example 8, VP101(M) is also referred to herein as VP101(hG1WT). This "wild-type" VP101(M) employs the Ig gamma-1 chain C region, ACCESSION: P01857, as the heavy chain constant region and the Ig kappa chain C region, ACCESSION: P01834, as the light chain constant region.
[0393] Amino acid sequence of the heavy chain of the immunoglobulin portion of VP101 (hG1WT): (453 aa)
[0394] Nucleic acid sequence encoding the heavy chain of the immunoglobulin portion of VP101 (hG1WT): (1359 bp)
[0395] To distinguish it from the mutated antibody described in Preparation Example 8, VP101(G4M) is also referred to herein as VP101(hG4WT). This wild-type VP101(G4M) employs the Ig gamma-4 chain C region, ACCESSION: P01861.1, as the heavy chain constant region and the Ig kappa chain C region, ACCESSION: P01834, as the light chain constant region.
[0396] Amino acid sequence of the heavy chain of the immunoglobulin portion of VP101 (hG4WT): (450 aa)
[0397] Nucleic acid sequence encoding the heavy chain of the immunoglobulin portion of VP101 (hG4WT): (1350 bp)
[0398] Preparation Example 8: Design of amino acid mutations in the non-variable region of the humanized bispecific antibody VP101 (hG1WT)
[0399] Based on VP101 (hG1WT) obtained in Preparation Example 7, the present inventors obtained VP101 (hG1DM) by introducing a point mutation from leucine to alanine (L234A) at position 234 of its heavy chain and a point mutation from leucine to alanine (L235A) at position 235.
[0400] Amino acid sequence of the heavy chain of the immunoglobulin portion of VP101 (hG1DM): (453 aa, the mutation site is underlined)
[0401] Nucleic acid sequence encoding the heavy chain of the immunoglobulin portion of VP101 (hG1DM): (1359 bp, mutation sites are underlined)
[0402] The light chain amino acid sequences of the immunoglobulin portions of VP101 (hG1DM), VP101 (hG1WT), and VP101 (hG4WT) are identical, as are their encoding nucleic acid sequences.
[0403] Amino acid sequence of the light chain of the immunoglobulin portion of VP101 (hG1DM): (214 aa)
[0404] Nucleic acid sequence encoding the light chain of the immunoglobulin portion of VP101 (hG1DM): (642 bp)
[0405] Experimental Example 1: Mixed Lymphocyte Reaction Detection of the Effect of Combination of Anti-CTLA4-Anti-PD-1 Bispecific Antibody and Anti-PD-1-Anti-VEGFA Bispecific Antibody on the Secretion of Cytokine IL-2
[0406] Two days before the experiment, PBMC (from healthy donors) were resuscitated and cultured in complete medium at 37°C in a 5% carbon dioxide incubator. After 2 hours, the PBMCs were allowed to recover and stimulated with SEB (final concentration 0.5 μg / mL) for two days. On the day of the experiment, Raji-PDL1 cells were collected, centrifuged, resuspended and counted (resuspended with 1640+10% FBS), the cell density was adjusted to 200 W / mL, and MMC (Mito-mycin C, final concentration 2 μg / mL) was added and treated at 37°C in a 5% carbon dioxide incubator for 1 hour. PBMCs stimulated for two days with SEB and Raji-PDL1 cells treated with MMC were collected, washed twice with 1640 basal medium, and the cells were resuspended in analysis medium and counted. The number of cells was 100,000 / well for PBMCs and 100,000 / well for Raji-PDL1. 100,000 cells / well (40 μL / well each) were seeded into 96-well U-shaped plates (Corning, model 3799). Drugs were added according to the experimental design, and blank controls (Raji cells alone and PBMCs alone) and negative controls (Raji cells + PBMCs and Raji + PBMCs + VEGF) were set up. The cells were co-cultured for 3 days (final volume of the system was 200 μL). The final concentrations of the first and second bispecific antibodies in combination were 3, 30, or 300 nM. When VEGF was added, the final concentration of VEGF-his (Kangfang Biopharmaceuticals, batch number: 20180126-1) was 500 ng / mL (VEGF in the experiment was VEGFA). After 3 days, the cells were centrifuged at 250 x g for 5 minutes (Beckman centrifuge), and the supernatant was collected and assayed for IL-2 content using a Dakota kit.
[0407] The results are shown in Figure 1. The results showed that in mixed culture systems with and without VEGF, the anti-CTLA4-anti-PD-1 bispecific antibody BiAb004 (hG1TM) and the anti-PD-1-anti-VEGFA bispecific antibody VP101 (hG1DM), used alone or in combination, significantly induced further IL-2 secretion from PBMCs. Furthermore, at the same final antibody concentration, the combined effect was superior to that of either bispecific antibody used alone at the same dose.
[0408] Experimental Example 2: Mixed Lymphocyte Reaction Detection of Cytokine Secretion Promoted by Anti-CTLA4-Anti-PD-1 Bispecific Antibody Combined with Anti-PD-1-Anti-VEGFA Bispecific Antibody
[0409] Normal human PBMCs were isolated using the separation medium Ficoll-Paque™ Plus (GE, Cat. No. 17-1440-02) according to the instructions. The day before the experiment, PBMCs were resuscitated and cultured in complete medium at 37°C in a 5% CO2 incubator. On the day of the experiment, PBMCs were collected, centrifuged, resuspended, counted, and the cell density was adjusted to 1*10 5 / well were inoculated into 96-well U-shaped plates (Corning, 3799); drugs were added according to the experimental design, wherein VEGF (prepared by Kangfang Biotechnology, batch number: 20210508) was incubated with the antibody at room temperature for 30 min (the VEGF in the experiment was VEGFA). At the same time, a negative control (PBMC+SEB+A549 cells+VEGF group, i.e., a group without antibody) and an isotype control (PBMC+SEB+A549 cells+VEGF+hIgG1DM group, i.e., the hIgG1DM group in the figure) were set up and incubated with PBMC at 37°C in a 5% carbon dioxide incubator for 30 min; A549 lung cancer cells (purchased from the Chinese Academy of Sciences, product number: SCSP-503) were routinely collected, resuspended by centrifugation, counted, and the cell density was adjusted to 1*10 4 Cells were seeded into each well of the aforementioned 96-well U-shaped plate. SEB (final concentration 0.1 μg / mL) (Toxin technology, Catalog No. BT202) was added and cultured for 3 days (final volume 200 μL). After 3 days, cells were centrifuged at 250 x g for 5 minutes (Beckman centrifuge), and the supernatant was collected and assayed for IFN-γ content using a Dakoway kit (Dakoway, Catalog No. 1110002).
[0410] The results are shown in Figure 2. The results showed that compared with isotype control antibodies, the anti-PD-1-anti-VEGFA bispecific antibody VP101 (hG1DM) and the anti-CTLA4-anti-PD-1 bispecific antibody BiAb004 (hG1TM) were both able to effectively promote the secretion of the cytokine IFN-γ in the mixed lymphoid system, and the BiAb004 (hG1TM) + VP101 (hG1DM) combination group exhibited a combined anti-tumor effect. The combined activity in promoting cytokine IFN-γ secretion was superior to that of each single-drug group at the same dose, and the activity of the 150nM BiAb004 (hG1TM) + VP101 (hG1DM) combination was superior to that of 300nM VP101 (hG1DM) alone.
[0411] Although specific embodiments of the present invention have been described in detail, it will be understood by those skilled in the art that various modifications and substitutions may be made to those details in light of all the teachings disclosed herein, and such modifications are within the scope of the present invention. The full scope of the present invention is given by the appended claims and any equivalents thereof.
Claims
1. A pharmaceutical combination comprising an effective amount of a first bispecific antibody and an effective amount of a second bispecific antibody, wherein: (1) A first bispecific antibody comprising: Targeting the first protein functional region of PD-1, and Targeting the second protein functional domain of CTLA4; Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or, the first protein functional region is a single-chain antibody, and the second protein functional region is an immunoglobulin; in, The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:30-32, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:33-35, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:36-38, respectively; or, The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:33-35, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:36-38, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs:30-32, respectively; (2) a second bispecific antibody comprising: Targeting the first protein functional region of PD-1, and Targeting the second protein functional domain of VEGFA; Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; or, the first protein functional region is a single-chain antibody, and the second protein functional region is a single-chain antibody. The region is immunoglobulin; in, The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 with amino acid sequences as shown in SEQ ID NOs:58-60, respectively, and whose light chain variable region comprises LCDR1-LCDR3 with amino acid sequences as shown in SEQ ID NOs:61-63, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 with amino acid sequences as shown in SEQ ID NOs:27-29, respectively, and whose light chain variable region comprises LCDR1-LCDR3 with amino acid sequences as shown in SEQ ID NOs:30-32, respectively; or, The immunoglobulin, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs: 27-29, respectively, and its light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs: 30-32, respectively; and the single-chain antibody, whose heavy chain variable region comprises HCDR1-HCDR3 as shown in SEQ ID NOs: 58-60, respectively, and its light chain variable region comprises LCDR1-LCDR3 as shown in SEQ ID NOs: 61-63, respectively.
2. The pharmaceutical combination according to claim 1, wherein: In item (1), the immunoglobulin is of human IgG1 subtype; preferably, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations: L234A and L235A; or L234A and G237A; or L235A and G237A; or L234A, L235A, and G237A; and / or In item (2), the immunoglobulin is of human IgG1 subtype; preferably, according to the EU numbering system, the heavy chain constant region of the immunoglobulin has one of the following mutation combinations: L234A and L235A; or L234A and G237A; or L235A and G237A; or L234A, L235A and G237A.
3. The pharmaceutical combination according to any one of claims 1 to 2, wherein In item (1): The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 14 and SEQ ID NO: 18; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 41 and SEQ ID NO: 43; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 42 and SEQ ID NO: 44; or, The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10, SEQ ID NO: 41 and SEQ ID NO: 43; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from the group consisting of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 42 and SEQ ID NO: 44; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 14 and SEQ ID NO: 18; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from the group consisting of SEQ ID NO: 16 and SEQ ID NO:
20.
4. The pharmaceutical combination according to any one of claims 1 to 3, wherein The feature of item (1) is selected from any one of the following 1) to 20): 1) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; 2) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 8; 3) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 12; 4) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 4; 5) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 8; 6) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 12; 7) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16; 8) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 2, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 4; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20; 9) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 8; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16; 10) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 6, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 8; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20; 11) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 12; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16 shown; 12) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 10, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 12; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20; 13) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 41, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 42; 14) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44; 15) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 41, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 42; 16) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44; 17) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:41, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:42; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:16; 18) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 44; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16; 19) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:41, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:42; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:20; as well as, 20) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:43, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:44; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO:18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:
20.
5. The pharmaceutical combination according to any one of claims 1 to 4, wherein In item (1): The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO:
24.
6. The pharmaceutical combination according to any one of claims 1 to 5, wherein In item (1): The first bispecific antibody comprises: Targeting the first protein functional region of PD-1, and Targeting the second protein functional domain of CTLA4; The number of the first protein functional region is one, and the number of the second protein functional region is two; Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 40, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 24; The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 43, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 44; The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin; The first protein functional region and the second protein functional region are connected by a first connecting fragment; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second connecting fragment; the first connecting fragment and the second connecting fragment are the same or different; Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 25 and SEQ ID NO: 26; Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are both as shown in SEQ ID NO:
26.
7. The pharmaceutical combination according to any one of claims 1 to 6, wherein In item (2): The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:45; and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO:47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is selected from SEQ ID NO:14 and SEQ ID NO:18; and the amino acid sequence of the light chain variable region of the single-chain antibody is selected from SEQ ID NO:16, SEQ ID NO:20 and SEQ ID NO:49; or, The amino acid sequence of the heavy chain variable region of the immunoglobulin is selected from SEQ ID NO: 14 and SEQ ID NO: 18; and the amino acid sequence of the light chain variable region of the immunoglobulin is selected from SEQ ID NO: 16, SEQ ID NO: 20 and SEQ ID NO: 49; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45; and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:
47.
8. The pharmaceutical combination according to any one of claims 1 to 7, wherein The feature of item (2) is selected from any one of the following 1) to 12): 1) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16; 2) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20; 3) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and, the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49; 4) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 16; 5) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 20; 6) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 47; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49; 7) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; 8) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO:
14. The amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; 9) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 14, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 49; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; 10) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 16; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; 11) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 20; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 47; and 12) The amino acid sequence of the heavy chain variable region of the immunoglobulin is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the immunoglobulin is shown in SEQ ID NO: 49; and the amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 45, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO:
47.
9. The pharmaceutical combination according to any one of claims 1 to 8, wherein In item (2): The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 54, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO:
56.
10. The pharmaceutical combination according to any one of claims 1 to 9, wherein In item (2): The second bispecific antibody comprises: Targeting the first protein functional region of PD-1, and Targeting the second protein functional domain of VEGFA; The number of the first protein functional region is one, and the number of the second protein functional region is two; Wherein, the first protein functional region is an immunoglobulin, and the second protein functional region is a single-chain antibody; The amino acid sequence of the heavy chain of the immunoglobulin is shown in SEQ ID NO: 54, and the amino acid sequence of the light chain thereof is shown in SEQ ID NO: 56; The amino acid sequence of the heavy chain variable region of the single-chain antibody is shown in SEQ ID NO: 18, and the amino acid sequence of the light chain variable region of the single-chain antibody is shown in SEQ ID NO: 49; The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin; The first protein functional region and the second protein functional region are connected by a first connecting fragment; and the heavy chain variable region of the single-chain antibody and the light chain variable region of the single-chain antibody are connected by a second connecting fragment; the first connecting fragment and the second connecting fragment are the same or different; Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are independently selected from SEQ ID NO: 25 and SEQ ID NO: 26; Preferably, the amino acid sequences of the first connecting fragment and the second connecting fragment are both as shown in SEQ ID NO:
26.
11. The pharmaceutical combination according to any one of claims 1 to 10, wherein In item (1) and / or item (2): The first protein functional region is directly connected to the second protein functional region or connected through a connecting fragment; and / or the heavy chain variable region of the single-chain antibody is directly connected to the light chain variable region of the single-chain antibody or connected through a connecting fragment.
12. The pharmaceutical combination according to claim 11, wherein In item (1) and / or item (2): The connecting fragment is (GGGGS)n, where n is a positive integer; preferably, n is 1, 2, 3, 4, 5 or 6.
13. The pharmaceutical combination according to any one of claims 1 to 12, wherein In item (1) and / or item (2): The first protein functional region and the second protein functional region are independently one, two or more.
14. The pharmaceutical combination according to any one of claims 1 to 13, wherein In item (1) and / or item (2): The single-chain antibody is linked to the C-terminus or N-terminus of the heavy chain of the immunoglobulin.
15. The pharmaceutical combination according to any one of claims 1 to 14, wherein The first bispecific antibody and the second bispecific antibody are mixed together, and the drug combination is a pharmaceutical composition.
16. The pharmaceutical combination according to any one of claims 1 to 15, wherein The first bispecific antibody and the second bispecific antibody are in separate packages, and the drug combination is a combination product.
17. The pharmaceutical combination according to any one of claims 1 to 16, wherein The mass ratio of the first bispecific antibody to the second bispecific antibody is (10:1) to (1:5), preferably (5:1) to (1:3) or (3:1) to (1:2), and more preferably 2:
1.
18. The pharmaceutical combination according to any one of claims 1 to 17, wherein Calculated based on the mass of the first bispecific antibody or the second bispecific antibody, the unit dose of the first bispecific antibody and the second bispecific antibody is independently 100 mg-2500 mg, 100 mg-2000 mg, 100 mg-1500 mg, 100 mg-1200 mg, 100 mg-1000 mg, 200 mg-800 mg, 200 mg-500 mg, 300 mg-600 mg, 400 mg-500 mg or 450 mg.
19. The pharmaceutical combination according to any one of claims 1 to 18, wherein The drug combination further comprises an effective amount of tumor chemotherapy drugs, such as alkylating agents, antimetabolites, antitumor antibiotics, plant-based anticancer drugs, hormones or immune preparations.
20. The pharmaceutical combination according to any one of claims 1 to 19, wherein The pharmaceutical combination further comprises one or more pharmaceutically acceptable excipients; preferably, also comprises product instructions.
21. Use of the pharmaceutical combination according to any one of claims 1 to 20 in the preparation of a medicament for treating or preventing tumors; Preferably, the tumor is selected from one or more of pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell cancer, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma; Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer; Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma; Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma; Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype: Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
22. The pharmaceutical combination according to any one of claims 1 to 20, for use in treating or preventing tumors; Preferably, the tumor is selected from one or more of pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell cancer, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma; Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer; Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma; Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma; Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype: Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
23. A method for treating or preventing tumors, comprising the step of administering to a subject in need thereof an effective amount of the pharmaceutical combination according to any one of claims 1 to 20; Preferably, the tumor is selected from pancreatic cancer, breast cancer, ovarian cancer, colorectal cancer, cervical cancer, plasma cell carcinoma, head and neck cancer, brain cancer, pharyngeal cancer, nasopharyngeal cancer, esophageal cancer, esophageal squamous cell carcinoma, thyroid cancer, mesothelioma, lung cancer, breast cancer, liver cancer, gastric cancer, biliary tract cancer, kidney cancer, fallopian tube cancer, endometrial cancer, cervical cancer, bladder cancer, urothelial carcinoma, prostate cancer, One or more of: cancer, testicular cancer, skin cancer, melanoma, myeloma, plasma cell cancer, vulvar cancer, leukemia, lymphoma, bone cancer, and osteosarcoma; Preferably, the lung cancer is selected from one or more of non-small cell lung cancer, small cell lung cancer and squamous cell lung cancer; Preferably, the gastric cancer is gastric adenocarcinoma or esophageal junction adenocarcinoma; Preferably, the lymphoma is Hodgkin's lymphoma or non-Hodgkin's lymphoma; Preferably, the tumor is a solid tumor with an MSI-H / dMMR phenotype; preferably, the tumor is selected from one or more of the following tumors with an MSI-H / dMMR phenotype: Colon cancer, rectal cancer, endometrial cancer, gastric cancer, mesothelioma, sarcoma, adrenocortical carcinoma, malignant melanoma and ovarian germ cell tumors.
24. The method according to claim 23, wherein The first bispecific antibody and the second bispecific antibody are independently administered before or after surgery, and / or before or after radiotherapy.
25. The method according to any one of claims 23 to 24, wherein: The single administration dose of the first bispecific antibody and the second bispecific antibody is independently 0.1-100 mg per kilogram of body weight, preferably 5-50 mg or 5-15 mg per kilogram of body weight; The first bispecific antibody and the second bispecific antibody are independently administered once every half a day, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 10 days, 1 week, 2 weeks or 3 weeks; and / or The administration method is intravenous drip, intravenous injection, subcutaneous injection or intraperitoneal injection.
